Histochemistry 52:273279 Nei Y, Obata-Ninomiya K, Tsutsui H, Ishiwata K, Miyasaka M, Matsumoto K, Nakae S, Kanuka H, Inase N, Karasuyama H (2013) GATA-1 regulates the generation and function of basophils
Serum T 3 level was 123 ng/dl, and the RAIU was 16% at 4 hours and 32% at 24 hours
This barrier acts as a gatekeeper, allowing nutrients to enter your bloodstream while keeping out undigested food particles and environmental toxins
Benefits (Research Focus) FOXO4-p53 PPI research studied as a selective disruptor of the FOXO4p53 protein-protein interaction in cellular research models p53 transactivation domain pharmacology investigated for targeting the p53 transactivation domain surface in PPI inhibitor research Cellular senescence research explored for senescence-associated apoptosis pathway endpoints in cell culture research models D-retro-inverso peptide chemistry examined for peptidase resistance and SAR studies of D-amino-acid sequence-reversed peptide design SASP marker research researched for senescence-associated secretory phenotype marker dynamics (p16, IL-6) in cell research What Researchers Look At FOXO4-p53 binding interface analysis and competitive PPI disruption assays p16 INK4a , IL-6, and other SASP marker expression in senescent cell research models Apoptosis induction (caspase activation, Annexin V staining) in senescent versus non-senescent cell research D-retro-inverso versus L-peptide comparative stability and biological activity research Comparative pharmacology versus other senolytic research compounds and PPI inhibitors Quick Specs Form: Lyophilized white powder Net Peptide Content: 10 mg per vial Quantity: 1 vial Appearance: White to off-white lyophilizate Reconstitution: Bacteriostatic or sterile water (added by the end researcher) Purity: 99% by HPLC Identity: MS-verified (per COA) Storage: Protect from light Identity Basics Compound: FOXO4-DRI Synonyms: FOXO4 D-retro-inverso peptide
August 2024 Passt gut Passt gut 21
Microglia exhibiting neuroinflammatory signatures expanded with disease progression (such as GPNMB, THEMIS, PVALB , and WIF1 )
